Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737710 · ClinicalTrials.gov registry record · NA
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 368
- Enrollment target
NCT01737710 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 368 participants.
The verdict
NCT01737710, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 368 participants
- Enrollment target
Study Summary
Atopic dermatitis, also called eczema, is a disease in which the skin is dry and scaly with severe itching. People who have atopic dermatitis often have complications from skin infections; these can include eczema herpeticum after herpes simplex virus infection or eczema vaccinatum after smallpox vaccination. People with atopic dermatitis may suffer from skin infections and may therefore respond differently to vaccinations. A new flu vaccine which is injected into the skin instead of into muscle has recently been approved by the Food and Drug Administration for vaccination of the general population including patients with atopic dermatitis. This new vaccine has been shown to work as well as the vaccine which is injected into muscle when tested in people without atopic dermatitis. The main purpose of this study is to compare how people with atopic dermatitis respond to this new flu vaccine compared to non-atopic volunteers without atopic dermatitis. The second purpose is to look at how people with atopic dermatitis respond to the new vaccine which is injected into the skin compared to the vaccine which is injected into muscle.
Interventions
- BIOLOGICAL Fluzone® Intradermal Vaccine
- BIOLOGICAL Fluzone® (Intramuscular) vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737710
The ClinicalTrials.gov registry entry for NCT01737710 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone® Intradermal Vaccine is the first listed.
NCT01737710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737710 about?
NCT01737710 is a clinical study titled "Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study". Atopic dermatitis, also called eczema, is a disease in which the skin is dry and scaly with severe itching. People who have atopic dermatitis often have complications from skin infections; these can include eczema herpeticum after herpes simplex virus infection or eczema vaccinatum after smallpox va...
What is the current status of trial NCT01737710?
This trial is currently completed. It is a NA study. The enrollment target is 368 participants. The study started on 2012-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01737710?
The interventions under investigation include: Fluzone® Intradermal Vaccine (BIOLOGICAL), Fluzone® (Intramuscular) vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01737710?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.